Biopharmaceuticals are shaping the future of modern healthcare and India is well-positioned to emerge as a global leader in this transformative sector. The Government of India is committed to strengthening innovation, manufacturing, clinical research, and regulatory capabilities to make India a leading global biopharmaceutical hub, said Anupriya Patel, Union Minister of State for Chemicals and Fertilisers.

Speaking at the 2nd Pharma Summit and Awards 2026 organised by ASSOCHAM in New Delhi, the minister said Biopharma SHAKTI initiative envisages launch of 100 biologics by 2047, contributing directly to the goals of Viksit Bharat and Swasth Bharat. She stated that the government has created strong funding and policy pathways across the pharmaceutical value chain.

Noting that biologics are expected to account for nearly 40 percent of prescription drugs by 2031, the minister emphasised that India must strengthen its capabilities in next-generation biologics while building on its established leadership in affordable generic medicines.

The minister further highlighted the growing importance of advanced therapies and noted that initiatives such as the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) Scheme and National Biopharma Mission are helping create a robust ecosystem for innovation, research, and manufacturing.

Industrial and manufacturing-related innovations are being supported through Biotechnology Industry Research Assistance Council (BIRAC) initiatives such as the Biotech Ignition Grant, Small Business Innovation Research Initiative (SBIRI), and Biotechnology Industry Partnership Programme (BIPP).

She said these programs are giving a strong fillip to innovation and called upon the industry to collaborate to place India firmly on the global map of novel biologics, while continuing to strengthen its leadership in small molecules and affordable medicines.

Addressing the gathering, Manoj Joshi, Secretary, Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, stressed on the need to strengthen innovation, accelerate drug discovery, support emerging biopharma capabilities, and build greater supply chain resilience.

Highlighting the transformative potential of the biopharmaceutical sector, he underscored the importance of the Biopharma SHAKTI initiative, which aims to position India as a global hub for the development and manufacturing of high-value biologics and biosimilars.

He noted that the initiative would strengthen research and innovation, expand clinical research infrastructure, build a skilled workforce, and enhance India’s competitiveness in the global biopharmaceutical value chain.

Patel also presented Pharma Excellence Awards to recognise outstanding contributions and achievements across the pharmaceutical sector at the Pharma Summit.